All In Biotech

Drug Trial Radar · NCT06671873

Study on Mass Balance of [14C]HMPL-306(Isocitrate Dehydrogenase Inhibitor) in Healthy Chinese Adult Male Subjects

A Single-center, Open-label, Single-dose Phase I Clinical Study to Investigate the Human Mass Balance in Healthy Chinese Adult Male Subjects Following a Single Oral Dose of 250 mg/100 µCi [14C] HMPL-306

Last checked: Nov 19, 2026Latest source record: Jul 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

6

Actual

Start

Nov 26, 2024

Primary completion

Feb 28, 2025

Study completion Jul 2, 2025

Sponsor

Lead sponsor
HutchmedIndustry
Sponsor type
Industry
First posted
Nov 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Health services research
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To evaluate the absorption, metabolism and excretion in healthy Chinese male subjects after a single oral dose of \[14C\]HMPL-306

Conditions

  • Mass Balance Study

Interventions

  • 100 µCi [14C] HMPL-306Drug

    D1: 250 mg/100 µCi \[14C\] HMPL-306 Single dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Human Mass BalanceTime frame: Day1~Day29
  2. Human Mass BalanceTime frame: Day-1~Day29
  3. Human Mass BalanceTime frame: Day-1~Day29
  4. Human Mass BalanceTime frame: Day-1~Day29
  5. Human Mass BalanceTime frame: Day-1~Day29

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital)

    Jinan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.